Carlsmed, Inc. (NASDAQ:CARL) Receives Average Recommendation of “Hold” from Brokerages

Carlsmed, Inc. (NASDAQ:CARL) has earned an average recommendation of “Hold” from the five ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $21.3333.

CARL has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e-)” rating on shares of Carlsmed in a research note on Monday, December 22nd. The Goldman Sachs Group restated a “buy” rating and set a $20.00 price target on shares of Carlsmed in a research note on Friday, January 9th. Wall Street Zen raised shares of Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Zacks Research raised shares of Carlsmed from a “strong sell” rating to a “hold” rating in a report on Thursday. Finally, BTIG Research reissued a “buy” rating and issued a $24.00 target price on shares of Carlsmed in a research report on Monday, December 15th.

Carlsmed Trading Down 2.0%

Shares of NASDAQ:CARL opened at $9.66 on Tuesday. The business’s 50-day moving average is $12.01 and its 200 day moving average is $12.94. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.87 and a quick ratio of 8.74. Carlsmed has a 1 year low of $9.55 and a 1 year high of $17.19. The firm has a market capitalization of $258.23 million and a P/E ratio of -2.64.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings results on Wednesday, February 25th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. Carlsmed had a negative return on equity of 72.60% and a negative net margin of 58.67%.The business had revenue of $15.16 million during the quarter, compared to the consensus estimate of $15.20 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. TD Waterhouse Canada Inc. acquired a new stake in shares of Carlsmed during the third quarter worth about $2,026,000. Teacher Retirement System of Texas acquired a new position in Carlsmed in the 3rd quarter worth approximately $2,343,000. Ghisallo Capital Management LLC acquired a new position in Carlsmed in the 3rd quarter worth approximately $670,000. Monashee Investment Management LLC purchased a new position in Carlsmed during the 3rd quarter worth approximately $536,000. Finally, Kornitzer Capital Management Inc. KS purchased a new position in Carlsmed during the 3rd quarter worth approximately $736,000.

Carlsmed Company Profile

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).